Eli Lilly and Co (LLY.N)
22 Jun 2018
COPENHAGEN, June 23 Diabetes drugmaker Novo Nordisk presented a post-hoc analysis of the SUSTAIN 7 trial comparing treatment effect in body weight across baseline BMI subgroups receiving Novo's Ozempic or Eli Lilly's dulaglutide, marketed as Trulicity.
* Drug priced at $25,000/year, 60 pct lower to AbbVie's Humira
LONDON, May 29 An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday.
* Zoetis says diagnostics should grow faster than animal health
Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.
May 14 Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company's experimental cancer treatment for solid tumors.
* ELI LILLY ANNOUNCES TENDER OFFER FOR HBM-PORTFOLIO COMPANY ARMO BIOSCIENCES FOR USD 1.6 BILLION
Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.
Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion (1.2 billion pounds) to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.
May 10 Drugmaker Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to get access to the drug developer's experimental cancer treatment.
|Johnson & Johnson (JNJ.N)||$122.84||+1.39|
|Pfizer Inc. (PFE.N)||$36.51||+0.21|
|Novartis AG (NOVN.S)||CHF75.60||+0.10|
|Merck & Co., Inc. (MRK.N)||$61.47||+0.29|
|Abbott Laboratories (ABT.N)||$61.94||+0.19|
|Sanofi SA (SASY.PA)||€69.01||+1.30|
|AstraZeneca plc (AZN.L)||5,229.00||-26.00|
|GlaxoSmithKline plc (GSK.L)||1,546.00||+7.60|
|Bristol-Myers Squibb Co (BMY.N)||$55.14||+1.20|
|Bristol-Myers Squibb Co (BMYMP.PK)||$919.60||+10.15|